ALK and inflammatory myofibroblastic tumor: None have experimented BRIGATINIB (To note: a clinical trial, NCT04925609, is currently in progress to study the efficacy of BRIGATINIB in a population of under 25-year-olds with ALK rearrangement with lymphoma, IMT or others solid tumors).